Oncology · Combination Therapy
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/18/2026, 6:30:54 AM
Assessment confidence: 82% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations. Assessment grounded in 19 ranked evidence items (16 high-relevance).
The strongest clinical anchor is Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea (ClinicalTrials.gov), entity match (selumetinib); patient population match (recurrent). In Oncology · Combination Therapy, 0 regulatory and 5 competitive items passed relevance filtering for AstraZeneca.
The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (astrazeneca). Secondary pressure from Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer.
Regulatory risk is concentrated around The trial results may lead to new indications or label expansions for selumetinib and olaparib, impacting regulatory strategies and compliance for companies involved in these therapies..
No evidence in this category.
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govhigh relevance
Entity match (selumetinib); Patient population match (recurrent)
FDA document
View sourceTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Entity match (oncology); Patient population match (recurrent)
FDA document
View sourcemTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (recurrent)
FDA document
View sourceA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
ClinicalTrials.govhigh relevance
Entity match (astrazeneca)
FDA document
View sourceTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Entity match (oncology)
FDA document
View sourceComparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceMerck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourcePhase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated
Humanexa Signalshigh relevance
Entity match (oncology)
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceTrial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Entity match (oncology)
FDA document
View sourceSentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceImmunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceCombination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedhigh relevance
Entity match (oncology)
FDA document
View sourceContrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceDiscovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe ongoing phase II trial of selumetinib and olaparib could redefine treatment protocols for RAS pathway mutant ovarian and endometrial cancers. Its outcomes may influence competitive positioning within the oncology landscape, particularly for combination therapies targeting these mutations.
Success in this trial could enhance market share for selumetinib and olaparib, positioning them as preferred options in a competitive market for targeted therapies, potentially affecting revenue streams for existing treatments.
The trial results may lead to new indications or label expansions for selumetinib and olaparib, impacting regulatory strategies and compliance for companies involved in these therapies.
Monitor trial results for efficacy data on tumor shrinkage and progression-free survival rates, as well as any updates on patient enrollment and safety profiles.
Track for follow-up milestones; no immediate action required.